Similarly, in the APPLE Phase II randomised trial, the detection of EGFR inhibitor resistance variants in non-small cell lung cancer patients receiving EGFR inhibitors allowed for earlier transitions and responses to the third-generation EGFR inhibitor, Osimertinib [130]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.